Pharma Stock Roundup: FDA Ok's Cancer Drugs for New Use, JNJ Stops US Baby Powder Sales
Zacks Investment Research | May 22, 2020 05:37AM ET
The FDA granted approval to Bristol-Myers Novartis’ gene therapy, Zolgensma to treat babies and young children with spinal muscular atrophy (SMA). Zolgensma was added to Novartis’ portfolio with the 2018 acquisition of AveXis. Zolgensma was approved by the FDA last year for the treatment of pediatric patients less than two years of age with SMA.
The NYSE ARCA Pharmaceutical Index declined 0.37% in the last five trading sessions.
Here is how the nine major stocks performed in the last five trading sessions.
Last week, AbbVie (NYSE:ABBV) rose the most (3.4%) while Merck declined the most (4.4%).
In the past six months, Lilly has risen the most (29.6%) while Merck declined the most (10.7%).
(See the last pharma stock roundup here: Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.